TELA Bio, Inc.

TELA Bio to Announce Third Quarter 2026 Financial Results

TELA Bio will report third quarter 2026 financial results on Tuesday, November 10, 2026, with management hosting a conference call and webcast at 4:30 p.m. ET that day. The announcement contains no financial figures, guidance, or other substantive news — it is purely a scheduling notice for the upcoming earnings release.

•5d ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio appointed Heather Getz as Chief Executive Officer and approved inducement grants totaling 2.37 million stock options and 500,000 restricted stock units effective August 3. The options package includes 1.365 million standard options with a strike price of $0.74 and 1.005 million premium-priced options at $0.90, all vesting over four years. Additionally, the company granted 95,500 RSUs to 11 other newly hired employees effective August 4 as part of their employment compensation.

•2mo ago

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELA Bio announced that it will participate in the Canaccord Genuity 46th Annual Growth Conference. Management is scheduled to present on August 12, 2026, at 8:30 am ET. Interested parties can access the live and archived webcast via the company's investor relations website.

•3mo ago

TELA Bio to Announce Second Quarter 2026 Financial Results

TELA Bio announced that it will report its second quarter 2026 financial results on Monday, August 10, 2026. Management is scheduled to host a conference call and webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. Investors must register online in advance to participate in the call, and a replay will be accessible via the company's website.

•3mo ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio approved inducement grants of restricted stock units covering 89,250 shares to 12 newly-hired employees under Nasdaq Rule 5635(c)(4). The grants were made on May 5, 2026, as a material inducement for each individual's acceptance of employment with the company. The restricted stock units will vest in equal annual installments over four years, subject to continued service through the vesting dates.

•5mo ago

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

TELA Bio announced a strategic board refreshment with four new appointments and preliminary Q1 2026 revenue of $19.0 million, topping guidance of $18.5 million. ANIK is mentioned only in the biography of incoming TELA director Joseph Capper, who has served on ANIK's board since May 2024. The release concerns TELA Bio's governance and financial performance; it contains no material news regarding Anika Therapeutics.

•6mo ago

TELA Bio to Announce First Quarter 2026 Financial Results

TELA Bio scheduled the release of its first quarter 2026 financial results for Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. Investors interested in listening to the call are required to register online in advance.

•6mo ago